

MCR MINI-UPDATE JULY 2018

Fellow Registrars,

I hope that you were able to enjoy some holiday time on the 4th. I used some vacation time to enjoy my flower garden last week, hence the delay in getting this to you. But I am happy to report that the delay has allowed me to include in this issue some important new updates from the standard setters.

DUE DATES

Large hospitals (>500 cases/yr.) are to report December 2017 cases by July 15 and smaller facilities (<300 cases /yr.) report the 4th Quarter of 2017 by July 15. **Please hold all cases diagnosed in 2018** until both your software and Web Plus are available in v18 layout.

EDUCATION

NAACCR Webinars

Live: July 12th, 2018, 8-11 a.m., **Hospital Cancer Registry Operations.** To attend the live broadcast in Columbia, sign up here: <https://www.signupgenius.com/go/30e0e49a4a82caafa7-naaccr30>.

NAACCR Recordings: Earn 3 CEs by viewing recorded webinars. Check out our Education and Training page to find out how you can receive access to the recorded NAACCR Webinars: <http://mcr.umh.edu/mcr-education.php>.

GoToMeeting/ZOOM Recordings: Previous GoToMeeting presentations are posted to the MCR website as recordings: <http://mcr.umh.edu/mcr-education.php>.

MCR Zoom Webinar

August 08, 2018, 10-11 a.m., “Grade 2018 Breast” Sign up here: <https://www.signupgenius.com/go/30e0e49a4a82caafa7-grade>.

Fundamentals of Abstracting Workshop

Fundamentals of Abstracting Workshop is a day and a half long course held at the offices of the Missouri Cancer Registry and Research Center in Columbia, MO. This class is geared toward **new abstractors** who are not familiar with the abstracting process and is free of charge. Students use Abstract Plus to work through cases using the MCR-ARC Abstract Code Manual. For those not familiar with abstracting and the MCR-ARC required fields, this is a great place to start. The next workshop is scheduled for Thursday August 16 from 1 p.m.-5 p.m. and Friday August 17 from 8 a.m.-4 p.m. Please register by Aug. 6th, 2018. To register: <https://www.signupgenius.com/go/30e0e49a4a82caafa7-fundamentals5>.

MCR MINI-UPDATE JULY 2018

Save the date for AJCC 8th Edition Cancer Staging Webinar for Registrars

The American Joint Committee on Cancer (AJCC) will be conducting a number of webinars on the AJCC Cancer Staging Manual, Eighth Edition in 2018. The webinars are scheduled as follows: July 25, 2018 - Head and Neck Staging; and Sept. 6, 2018 - Breast Staging. All webinars will be held from 1:00 to 2:00 p.m. CDT. Category A CE of 1 hour is available for each webinar. Attendance documentation is the responsibility of the attendee. AJCC will ONLY provide confirmation to NCRA for CE audits. Make sure to mark your calendars. Recordings will be posted to the AJCC website after the live webinars. Visit the AJCC website for updates, additional information and registration links:

<https://cancerstaging.org/CSE/Registrar/Pages/8thEditionWebinars.aspx>.

Grade Data Items and Radiation Data Items Webinars

A recording of the 2018 New Grade Coding Rules and New Radiation Coding Rules Webinar are now available at <https://www.naacr.org/2018-implementation/#Education>.

MCR Help-Line

Reach us at 1-800-392-2829 during regular office hours, or leave a message; a member of our QA team will return your call within one business day.

MCR NEWS

Gold Again!

Missouri Cancer Registry has once again been awarded NAACCR Gold Certification. Thanks to all of you for the contributions you made. We consider you co-recipients of this award when you assure timely case reporting; it is your expertise that contributes the high quality, complete data necessary to qualify for the Gold designation. It takes a team effort to achieve results like this. Considering the small number of staff many of us have compared w/ earlier years when we collected fewer data elements and had less complexity, this is awesome! Thanks again for your ongoing efforts and for your dedication and commitment to Missouri cancer surveillance.

Death Clearance

Death Clearance activities for reporting year 2016 are underway. Hospital and facility participation in the followback process is expected to begin early in August. Please stay tuned for further instructions and notifications through email when the official followback process begins.

New Change of Information Format

We have updated our MCR form for Change of Information (COI) on the MCR website at:

<http://mcr.umh.edu/mcr-cancer-reporting-hospital.php> A copy is also attached for your files. Fill out this form whenever one of the listed critical fields is changed within your database on a case that was previously submitted to MCR. The form now has space to add text to support the change to a new field code.

MCR MINI-UPDATE JULY 2018

NPCR Program Evaluation Instrument – MCR Data Use

The NPCR Program Evaluation Instrument (PEI) is a web-based survey of participating central registries designed to evaluate our operational attributes and progress toward meeting program standards. I thought that you might be interested in the section that summarized MCR data usage in 2017:

Data Use Category	Number per Year
Comprehensive cancer control detailed incidence/mortality estimates	6
Detailed incidence/mortality by stage and geographic area	7
Collaboration with cancer screening programs for breast, colorectal, or cervical cancer	6
Health event investigation(s)	7
Needs assessment/program planning (e. g. Community Cancer Profiles)	8
Program evaluation	4
Epidemiologic studies	3
Other: Grant apps; linkages; info requests; presentations- state, national & international; training sessions & webinars	30

The total of 71 grossly underestimates the number of times MCR, health depts., Missouri Cancer Consortium, reporting facilities, researchers and the general public used registry data via DHSS & MCR-ARC interactive websites. Your data is important and frequently used!

NAACCR 2018 Annual Conference in Pittsburgh

MCR-ARC Director Dr. Jeannette Jackson-Thompson, Senior Statistician Dr. Chester Schmaltz and Epidemiologist Dr. Yilin Yoshida attended the NAACCR Annual Conference in Pittsburgh last month. Jeannette took full advantage of opportunities to network, including an important face-to-face meeting with personnel key to our current CDC ovarian study. She moderated one of two student oral presentation sections and was quite impressed with the quality of work reported by the students. Jeannette reports that of the three awards given in the oral presentation category, first place went to a Missouri researcher, Dr. Nosayaba (Nosa) Osazuwa-Peters. Dr. Osazuwa-Peters, who trained and practiced as a dentist in Nigeria before moving to the US in 2009, received an MPH degree from Washington University in 2012 and a PhD from St. Louis University shortly before the conference. He presented "Nonclinical factors associated with head and neck cancer survivorship among patients with metastatic disease." Three awards were given in the student poster presentation category. Jiang Du, MCR-ARC's Statistics GRA, was entered in this category but could not compete since he didn't attend NAACCR -- he was in Las Vegas getting married before taking up a new position on the west coast after getting his PhD from Mizzou in May! Chester presented for Jiang; Chester also presented a poster on which he was lead author and gave an oral presentation (lead author Iris Zachary, PhD, MSHI, CTR) . Yilin represented MCR with a poster and brought back lots of ideas for future data analysis. Chester's, Jiang's and Yilin's presentations are available on the MCR-ARC website at <http://mcr.umh.edu/mcr-postersandpresentations.php>. Topics presented include:

- Schmaltz CL, Jackson-Thompson J, Du J, Francis B. Patterns and recent trends in mastectomy and breast conserving surgery for women with early-stage breast tumors in Missouri: An update and further investigation.

MCR MINI-UPDATE JULY 2018

- Du J, Sun D, Schmaltz CL, Jackson-Thompson J. A spatio-temporal investigation of breast cancer treatment delay in Missouri.
- Zachary I, Jackson-Thompson J, Schmaltz CL. Examining Subsequent Occurrence and Outcomes of Estrogen-related Cancers (Breast and Thyroid) in Missouri Women.
- Yoshida Y, Schmaltz CL, Jackson-Thompson J, Simoes EJ. Survival of female breast, cervical and colorectal cancers in Missouri, 1996-2015.

Once again, your data is getting international recognition via these presentations and posters!

ABSTRACTING TIPS

AJCC Group IV vs SEER Summary Stage 7

Be aware that an AJCC Stage IV for some sites does not automatically confer a SEER Summary Stage of 7, distant disease. For example, an AJCC Stage IVA or Stage IVB laryngeal primary could represent a SEER SS2018 stage 3 or 4 if regional lymph nodes meet criteria for AJCC N2 or N3. Don't assume you are comparing apples to apples—Look up the code definitions to get it right!

STANDARD SETTER AND NATIONAL NEWS

CDC/NPCR

2018 Required Fields!

Final clarification regarding interpretation of the CDC/NPCR 2018 Required Fields List was emailed to us and I have quickly incorporated their requirements into the MCR 2018 Required Fields List which is finally ready for publication. I have attached a copy to this email and it will be posted to our website shortly. New fields are marked in bold font. Fingers crossed that no more changes come down the pipeline! Thank you for your patience, this has been a difficult year for standard setters and central registries. CoC facilities will report TNM fields and many of the Site Specific Data Items which they are collecting for the NCDB to MCR as well. Non-CoC accredited facilities are not required to report TNM and have only a limited number of SSDI fields which replace previous SSFs. The new fields will be in your v18 software; until you upgrade, you may want to make notes in text boxes regarding information gathered for new fields. This could save you having to return to the medical record when completing the case after your software upgrade. Explanations of all fields are in the NAACCR Data Dictionary and will be in the forthcoming STORE and MCR Manuals.

US Cancer Statistics – update released

The United States Cancer Statistics are combined cancer registry data from CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Together, these data provide the latest cancer information on the entire U.S. population. You can access the latest release of data through the updated [Data Visualizations Tool and Public Use Database](#)

Surveillance for Certain Health Behaviors and Conditions among States and Selected Local Areas – Behavioral Risk Factor Surveillance System, United States, 2015

This publication contains information on Tobacco Use.

https://www.cdc.gov/mmwr/volumes/67/ss/ss6709a1.htm?s_cid=ss6709a1_e

MCR MINI-UPDATE JULY 2018

NCI/SEER

More Final Solid Tumor Rules posted – important information

The final 2018 Solid Tumor **General Instructions** have been posted and may now be used only for those sites updated for 2018 and diagnosed 1/1/2018 forward. The **exception is Cutaneous Melanoma and Other Sites**; the **2007** Multiple Primary and Histology Coding General Instructions still apply to these two site groups. **DO NOT USE** the 2018 General Instructions for Cutaneous Melanoma tumors AND tumors covered in Other Sites. Using the 2018 Solid Tumor General Instructions for these site groups will result in histology coding errors.

The final 2018 Solid Tumor **Breast** Rules have been posted and now may be used for cases diagnosed 1/1/2018 forward. **IMPORTANT INFORMATION:** Major changes have been made to the 2018 Breast rules regarding histology coding. These comprehensive changes reflect WHO 4th Ed Breast Tumors and the 2018 In situ Breast CAP Protocol and Invasive Breast Carcinoma CAP Protocol. The editors of the 2018 Breast rules strongly recommend you read the Breast Terms & Definitions AND the Breast H Rules as they provide detailed instructions for coding breast histologies.

The final 2018 Solid Tumor **Colon** Rules have been posted and now may be used for cases diagnosed 1/1/2018 forward. **IMPORTANT INFORMATION:** Major changes have been made to the 2018 Colon rules regarding new tumors in anastomosis sites and histology coding in polyps. The editors of the 2018 Colon rules strongly recommend you read the Colon Terms & Definitions, M rules, and H rules as they provide detailed information and coding instructions for the rules specific to anastomosis recurrence and polyp histology.

The final 2018 Solid Tumor **Lung** Rules have been posted and now may be used for cases diagnosed 1/1/2018 forward. **IMPORTANT INFORMATION:** Major changes have been made to the 2018 Lung rules regarding histology coding. These comprehensive changes reflect WHO 4th Ed Tumors of Lung and the 2018 Lung CAP Protocol. The editors of the 2018 Lung rules strongly recommend you read the Lung Terms & Definitions AND the Lung H Rules as they provide detailed instructions for coding lung histologies.

Final Solid Tumor Rules may be accessed at the following link: <https://seer.cancer.gov/tools/solidtumor/>
The following sites are still marked DRAFT: Head & Neck, Malignant CNS & Peripheral Nerves, Non-Malignant CNS Tumors. Educational modules are being developed for each revised set of site rules and an email notice will be sent once they are available. Please direct questions concerning these rules to Ask A SEER Registrar.

NAACCR

Cancer in North America (CiNA) 2010-2015

The 28th edition of the publication Cancer in North America (CiNA): 2010-2015 is now available on the NAACCR web site. Please visit <https://www.naaccr.org/cancer-in-north-america-cina-volumes/> for free access/downloading of the publication. This year's publication includes cancer incidence data for all 50 U.S. states, the District of Columbia, Puerto Rico, and for 12 Canadian registries. We also report data separately by 5 regions: California (excluding the Greater Bay area and Los Angeles), and 4 SEER urban registries (Detroit, Los Angeles, San Francisco/Oakland, and Seattle).

This publication provides cancer incidence data as collected by the regional, state, provincial and territorial NAACCR member registries across North America. Incidence data were provided to NAACCR

MCR MINI-UPDATE JULY 2018

by the NAACCR member registries in the hopes of providing ready access to data across the United States and Canada. This publication is possible due to the ongoing and excellent efforts of our member registries to assemble high quality and timely cancer incidence data.

Volume One includes combined data for the United States, for Canada and for all of North America. The information in Volume One includes leading cancer types by sex and, for the United States, by race and ethnicity. Age-adjusted cancer rates by cancer type, pediatric cancer data and cancer data by stage for selected cancers. Delay-adjusted cancer incidence rates are also provided to improve the ability to assess trends.

Volume Two provides registry-specific incidence data by cancer site, sex, race, ethnicity and stage for all NAACCR members submitting data for inclusion in the monograph.

Volume Three includes information on cancer mortality death rates by cancer site, sex, race, and ethnicity.

Volume Four provides survival rates for North America, US and Canada as well as registry-specific survival for selected cancer types.

CoC

The STORE Manual is expected to be released soon. It will replace the FORDS manual beginning with cases diagnosed in 2018.

AJCC

TNM Manual Errata for 3rd printing too

Third printing of AJCC Cancer Staging Manual errata are listed on a separate tab of the errata spreadsheet at: <https://facsgroupdropbox.com/share/b9b52fb79502ded3aa25eae6e97cd157>. If you have purchased a third printing, there are 58 entries as of 6/29/18 that can be annotated in your copy.

NCRA

Users will NOT be able to login and access any learning activities from NCRA's Center for Cancer Registry Education beginning 8 AM ET on Friday, July 20 through 7 AM ET on Monday, July 23. NCRA thanks you for your patience. The system upgrade will allow NCRA to provide new options and services. Questions? Contact CCRE@ncra-usa.org or 703-299-6640 ext. 317.

REGISTRY TO RESEARCH & SURVEILLANCE (publications using cancer registry data!)

Urban Neighborhood and Residential Factors Associated with Breast Cancer in African American Women: a Systematic Review (data from several state registries)

<https://link.springer.com/article/10.1007%2Fs12672-018-0325-x>

Association between Intensity of Posttreatment Surveillance Testing and Detection of Colorectal Cancer Recurrence (NCDB special study data)

<https://jamanetwork.com/journals/jama/fullarticle/2681746>

MCR MINI-UPDATE JULY 2018

Association of Circulating Tumor Cell Status with Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer (NCDB data)

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2679564>

Higher Lung Cancer Incidence in Young Women than Young Men in the United States (NAACCR data)

<https://www.nejm.org/doi/full/10.1056/NEJMoa1715907>

Immediate breast reconstruction for women having inflammatory breast cancer in the United States (SEER data)

<https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.1546>

Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis (NCDB data)

[https://www.europeanurology.com/article/S0302-2838\(18\)30379-8/abstract](https://www.europeanurology.com/article/S0302-2838(18)30379-8/abstract)

Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group (data from European registries)

<https://www.nature.com/articles/s41416-018-0090-1>

Pancreatic Cancer Following Incident Diabetes in African Americans and Latinos: The Multiethnic Cohort (California Cancer Registry data)

<https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djy090/5036586>

Geographic Variation in Pediatric Cancer Incidence — United States, 2003–2014 (NPCR and SEER data)

https://www.cdc.gov/mmwr/volumes/67/wr/mm6725a2.htm?s_cid=mm6725a2_e

Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005–2015 (VA data)

<https://jamanetwork.com/journals/jama/article-abstract/2681802>

Male Breast Cancer: An Updated SEER Data Analysis

[https://www.clinical-breast-cancer.com/article/S1526-8209\(18\)30016-8/pdf](https://www.clinical-breast-cancer.com/article/S1526-8209(18)30016-8/pdf)

Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014 (NPCR and SEER data)

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2685651>

Palliative Care Reduces Odds of Suicide in Lung Cancer Patients (VA data)

https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A4167

Defining Survivorship Trajectories Across Patients With Solid Tumors An Evidence-Based Approach (SEER data)

<https://jamanetwork.com/journals/jamaoncology/fullarticle/2683252>

Breast Cancer Death Rates among Women Aged 50–74 Years, by Race/Ethnicity — National Vital Statistics System, United States, 2006 and 2016

<http://dx.doi.org/10.15585/mmwr.mm6721a8>

MCR MINI-UPDATE JULY 2018

RESOURCES AND NEWS OF INTEREST

Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.31379>

Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014

<https://www.nature.com/articles/s41375-018-0149-2>

Increasing prevalence of human papillomavirus–positive oropharyngeal cancers among older adults

<https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.31385>

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

<http://ascopubs.org/doi/abs/10.1200/JCO.2017.76.8192>

Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists

<https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy166/5004443>

Cancer prevalence among flight attendants compared to the general population

<https://ehjournal.biomedcentral.com/articles/10.1186/s12940-018-0396-8>

Patients could be spared life-long leukemia treatment, clinical trial finds

<https://medicalxpress.com/news/2018-06-patients-life-long-leukaemia-treatment-clinical.html>

How the polio virus is being used to combat brain cancer

<https://www.cnn.com/2018/06/26/health/brain-cancer-poliovirus-study/index.html>

AVATS: Awake Video Assisted Thoracic Surgery for Patients with Poor Pulmonary Function

https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A6416

There is meaning in the work we do together!

Nancy H. Rold, CTR

Operations Manager

Missouri Cancer Registry and Research Center

Missouri Cancer Registry Change of Information (COI) Form

Facility Name: _____ **FIN:** _____ **Date:** _____

No.	Last Name*	First Name*	DOB*	SSN*	Acc/Seq #*	COI		
						Item Name	From	To
1								
	Supporting Text or Comments:							
2								
	Supporting Text or Comments:							
3								
	Supporting Text or Comments:							
4								
	Supporting Text or Comments:							
5								
	Supporting Text or Comments:							
6								
	Supporting Text or Comments:							
7								
	Supporting Text or Comments:							
No.	Last Name*	First Name*	DOB*	SSN*	Acc/Seq #*	COI		

						Item Name	From	To
8								
	Supporting Text or Comments:							
9								
	Supporting Text or Comments:							
10								
	Supporting Text or Comments:							
11								
	Supporting Text or Comments:							
12								
	Supporting Text or Comments:							

***If listing several items for same patient, patient information need only be entered one time. See below for list of items required to be corrected.**

DATA ELEMENTS REQUIRING COI FORM - 2018

- | | |
|---|---|
| <ol style="list-style-type: none"> 1. Last name, first name, middle (including maiden name and alias) 2. Address at diagnosis, includes city, county, state and zip code 3. Race 4. Spanish/Hispanic origin 5. Sex 6. Birth date 7. Social security number 8. Date of diagnosis 9. Date of 1st Contact 10. Primary site (and any updates to affected fields: stage, surgery, etc) | <ol style="list-style-type: none"> 11. Morphology type, behavior and grade 12. Laterality 13. Diagnostic confirmation 14. Stage of disease 15. Type and start date of FIRST course of definitive treatment <p style="color: red; text-align: center;">(MCR-required fields only)</p> |
|---|---|

Item #	NPCR Status	MCR status	Item Name	Section	Note
10	R	R	Record Type	Record ID	
40	R	R	Registry ID	Record ID	
50	R	R	NAACCR Record Version	Record ID	
70	R	R	Addr at DX--City	Record ID	
80	R	R	Addr at DX--State	Record ID	
90	R	R	County at DX Reported	Demographic	Name change from County at Dx
100	R	R	Addr at DX--Postal Code	Demographic	
150	.	R	Marital Status at DX	Demographic	
160	R	R	Race 1	Demographic	
161	R	R	Race 2	Demographic	
162	R	R	Race 3	Demographic	
163	R	R	Race 4	Demographic	
164	R	R	Race 5	Demographic	
170	.	R	Race Coding System - Current		
190	R	R	Spanish/Hispanic Origin	Demographic	
220	R	R	Sex	Demographic	
230	R	R	Age at Diagnosis	Demographic	
240	R	R	Date of Birth	Demographic	
241	R	R	Date of Birth Flag	Demographic	
250	RH*	RH*	Birthplace	Demographic	1997-2012
252	R*	R*	Birthplace--State	Demographic	
254	R*	R*	Birthplace--Country	Demographic	
310	R*	R*	Text--Usual Occupation	Demographic	
320	R*	R*	Text--Usual Industry	Demographic	
390	R	R	Date of Diagnosis	Cancer Identification	
391	R	R	Date of Diagnosis Flag	Cancer Identification	
400	R	R	Primary Site	Cancer Identification	
410	R	R	Laterality	Cancer Identification	
420	RH	RH	Histology (92-00) ICD-O-2	Cancer Identification	1997-2002
430	RH	RH	Behavior (92-00) ICD-O-2	Cancer Identification	1997-2002
440	RH	RH	Grade	Cancer Identification	1997-2017
441	RH*	RH*	Grade Path Value	Cancer Identification	2011-2013
449	RH*	RH*	Grade Path System	Cancer Identification	2011-2013

450	R	R	Site Coding Sys--Current	Cancer Identification	
470	R	R	Morph Coding Sys--Current	Cancer Identification	
490	R	R	Diagnostic Confirmation	Cancer Identification	
500	R	R	Type of Reporting Source	Cancer Identification	
522	R	R	Histologic Type ICD-O-3	Cancer Identification	
523	R	R	Behavior Code ICD-O-3	Cancer Identification	
540	R	R	Reporting Facility	Hospital-Specific	
545	R*	R*	NPI--Reporting Facility	Hospital-Specific	
580	R	R	Date of 1st Contact	Hospital-Specific	
581	R	R	Date of 1st Contact Flag	Hospital-Specific	
610	R	R	Class of Case	Hospital-Specific	
630	R*	R*	Primary Payer at DX	Hospital-Specific	
756	R	R	Tumor Size Summary	Stage/Prognostic Factors	
759	RH	RH	SEER Summary Stage 2000	Stage/Prognostic Factors	2001-2003, 2015-2017
760	RH	RH	SEER Summary Stage 1977	Stage/Prognostic Factors	1997-2000
764	R	R	Directly Assigned SS2018	Stage/Prognostic Factors	NEW
820	R	R	Regional Nodes Positive	Stage/Prognostic Factors	
830	R	R	Regional Nodes Examined	Stage/Prognostic Factors	
880	RH	RH	TNM Path T	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
890	RH	RH	TNM Path N	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
900	RH	RH	TNM Path M	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
910	RH	RH	TNM Path Stage Group	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
920	RH	RH	TNM Path Descriptor	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
940	RH	RH	TNM Clin T	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
950	RH	RH	TNM Clin N	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
960	RH	RH	TNM Clin M	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities

970	RH	RH	TNM Clin Stage Group	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
980	RH	RH	TNM Clin Descriptor	Stage/Prognostic Factors	2015 CoC facilities, 2016-2017 all facilities
995	D	D	AJCC ID	Stage/Prognostic Factors	New
1001	RN	CoC facilities only	AJCC TNM Clin T	Stage/Prognostic Factors	New
1002	RN	CoC facilities only	AJCC TNM Clin N	Stage/Prognostic Factors	New
1003	RN	CoC facilities only	AJCC TNM Clin M	Stage/Prognostic Factors	New
1004	RN	CoC facilities only	AJCC TNM Clin Stage Group	Stage/Prognostic Factors	New
1011	RN	CoC facilities only	AJCC TNM Path T	Stage/Prognostic Factors	New
1012	RN	CoC facilities only	AJCC TNM Path N	Stage/Prognostic Factors	New
1013	RN	CoC facilities only	AJCC TNM Path M	Stage/Prognostic Factors	New
1014	RN	CoC facilities only	AJCC TNM Clin Path Group	Stage/Prognostic Factors	New
1021	RN	CoC facilities only	AJCC TNM Post Therapy T	Stage/Prognostic Factors	New
1022	RN	CoC facilities only	AJCC TNM Post Therapy N	Stage/Prognostic Factors	New
1023	RN	CoC facilities only	AJCC TNM Post Therapy M	Stage/Prognostic Factors	New
1024	RN	CoC facilities only	AJCC TNM Post Therapy Stage Group	Stage/Prognostic Factors	New
1031	RN	CoC facilities only	AJCC TNM Clin T Suffix	Stage/Prognostic Factors	New
1032	RN	CoC facilities only	AJCC TNM Path T Suffix	Stage/Prognostic Factors	New
1033	RN	CoC facilities only	AJCC TNM Post Therapy T Suffix	Stage/Prognostic Factors	New
1034	RN	CoC facilities only	AJCC TNM Clin N Suffix	Stage/Prognostic Factors	New
1035	RN	CoC facilities only	AJCC TNM Path N Suffix	Stage/Prognostic Factors	New
1036	RN	CoC facilities only	AJCC TNM Post Therapy N Suffix	Stage/Prognostic Factors	New
1060	R	R	TNM Edition Number	Stage/Prognostic Factors	if TNM reported
1182	R*	R*	Lymph-vascular Invasion	Stage/Prognostic Factors	
1200	R	R	RX Date Surgery	Treatment-1st Course	
1201	R	R	RX Date Surgery Flag	Treatment-1st Course	
1210	R	R	RX Date Radiation	Treatment-1st Course	
1211	R	R	RX Date Radiation Flag	Treatment-1st Course	
1220	R	R	RX Date Chemo	Treatment-1st Course	
1221	R	R	RX Date Chemo Flag	Treatment-1st Course	
1230	R	R	RX Date Hormone	Treatment-1st Course	
1231	R	R	RX Date Hormone Flag	Treatment-1st Course	
1240	R	R	RX Date BRM	Treatment-1st Course	
1241	R	R	RX Date BRM Flag	Treatment-1st Course	

1250	R	R	RX Date Other	Treatment-1st Course	
1251	R	R	RX Date Other Flag	Treatment-1st Course	
1270	R#	R	Date 1st Crs RX CoC	Treatment-1st Course	
1271	R#	R	Date 1st Crs RX CoC Flag	Treatment-1st Course	
1280	.	R	RX Date DX/Stg Proc	Treatment-1st Course	
1281	.	R	RX Date Dx/Stg Proc Flag	Treatment-1st Course	
1285	R#	R	RX Summ--Treatment Status	Treatment-1st Course	
1290	R	R	RX Summ--Surg Prim Site	Treatment-1st Course	
1292	R	R	RX Summ--Scope Reg LN Sur	Treatment-1st Course	
1294	R	R	RX Summ--Surg Oth Reg/Dis	Treatment-1st Course	
1340	R	R	Reason for No Surgery	Treatment-1st Course	
1350	.	R	RX Summ – DX/Stg Proc	Treatment-1st Course	
1360	RH	RH	RX Summ--Radiation	Treatment-1st Course	1997-2002
1380	R	R	RX Summ--Surg/Rad Seq	Treatment-1st Course	
1390	R	R	RX Summ--Chemo	Treatment-1st Course	
1400	R	R	RX Summ--Hormone	Treatment-1st Course	
1410	R	R	RX Summ--BRM	Treatment-1st Course	
1420	R	R	RX Summ--Other	Treatment-1st Course	
1430	R	R	Reason for No Radiation	Treatment-1st Course	
1460	R	R	RX Coding System--Current	Treatment-1st Course	
1506	R	R	Phase I Radiation Treatment Modality	Treatment-1st Course	New
1570	RH	RH	Rad--Regional RX Modality	Treatment-1st Course	2003-2017, replaced by item 1506 in 2018
1639	R	R	RX Summ--Systemic/Sur Seq	Treatment-1st Course	
1750	R	R	Date of Last Contact	Follow-up/Recurrence/Death	
1751	R	R	Date of Last Contact Flag	Follow-up/Recurrence/Death	
1760	R	R	Vital Status	Follow-up/Recurrence/Death	
1770	.	R	Cancer Status		
1790	R*	R*	Follow-Up Source	Follow-up/Recurrence/Death	
1810	.	R	Addr Current--City		
1820	.	R	Addr Current--State		

1830	.	R	Addr Current--Postal Code		
1840	.	R	County--Current		
1910	R	R	Cause of Death	Follow-up/Recurrence/Death	
1920	R	R	ICD Revision Number	Follow-up/Recurrence/Death	
1940	RH	RH	Place of Death	Follow-up/Recurrence/Death	1997-2012
1942	R	R	Place of Death--State	Demographic	
1944	R*	R	Place of Death--Country	Demographic	
1985	.	R	Over-ride Acsn/Class/Seq	Edit Overrides/Conversion History/System Admin	
1986	.	R	Over-ride HospSeq/DxConf	Edit Overrides/Conversion History/System Admin	
1988	.	R	Over-ride HospSeq/Site	Edit Overrides/Conversion History/System Admin	
1989	R	R	Over-ride Site/TNM-StgGrp	Edit Overrides/Conversion History/System Admin	
1990	R	R	Over-ride Age/Site/Morph	Edit Overrides/Conversion History/System Admin	
1992	RN	R	Over-ride TNM Stage	Edit Overrides/Conversion History/System Admin	New for use if TNM is reported
1993	RN	R	Over-ride TNM Tis	Edit Overrides/Conversion History/System Admin	New for use if TNM is reported
1994	RN	R	Over-ride TNM 3	Edit Overrides/Conversion History/System Admin	New for use if TNM is reported
2000	R	R	Over-ride SeqNo/DxConf	Edit Overrides/Conversion History/System Admin	
2010	R	R	Over-ride Site/Lat/SeqNo	Edit Overrides/Conversion History/System Admin	
2020	R	R	Over-ride Surg/DxConf	Edit Overrides/Conversion History/System Admin	
2030	R	R	Over-ride Site/Type	Edit Overrides/Conversion History/System Admin	

2040	R	R	Over-ride Histology	Edit Overrides/Conversion History/System Admin	
2050	R	R	Over-ride Report Source	Edit Overrides/Conversion History/System Admin	
2060	R	R	Over-ride Ill-define Site	Edit Overrides/Conversion History/System Admin	
2070	R	R	Over-ride Leuk Lymphoma	Edit Overrides/Conversion History/System Admin	
2071	R	R	Over-ride Site/Behavior	Edit Overrides/Conversion History/System Admin	
2074	R	R	Over-ride Site/Lat/Morph	Edit Overrides/Conversion History/System Admin	
2078	R	R	Over-ride Name/Sex	Edit Overrides/Conversion History/System Admin	New
2100	.	R	Date Case Last Changed	Edit Overrides/Conversion History/System Admin	
2110	R	R	Date Case Report Exported	Edit Overrides/Conversion History/System Admin	
2116	R	R	ICD-O-3 Conversion Flag	Edit Overrides/Conversion History/System Admin	
2152	R	R	CoC Accredited Flag	Edit Overrides/Conversion History/System Admin	New
2170	.	R	Vendor Name		
2220	.	R	MO Alcohol History		
2220	.	R	MO Tobacco History		
2220	.	R	MO Tobacco Years		
2220	.	R	MO Toxic Exposure 1		
2220	.	R	MO Toxic Exposure 2		
2220	.	R	MO Toxic Exposure 3		
2220	.	R	MO hx1 Personal Hx 1		
2220	.	R	MO hx1 Year 1		
2220	.	R	MO hx2 Personal Hx 2		
2220	.	R	MO hx2 Year 2		
2230	R	R	Name--Last	Patient-Confidential	
2240	R	R	Name--First	Patient-Confidential	

2250	R	R	Name--Middle	Patient-Confidential	
2280	R	R	Name--Alias	Patient-Confidential	
2290	.	R*	Name - Spouse/Parent		
2300	R	R	Medical Record Number	Patient-Confidential	
2320	R	R	Social Security Number	Patient-Confidential	
2330	R	R	Addr at DX--No & Street	Patient-Confidential	
2335	R	R	Addr at DX--Supplementl	Patient-Confidential	
2350	.	R	Addr Current--No & Street		
2360	.	R	Telephone		
2380	R	R	DC State File Number	Patient-Confidential	
2390	R	R	Name--Maiden	Patient-Confidential	
2410	.	R	Institution Referred From		
2440	.	R	Institution Referred To		
2520	R^	R	Text--DX Proc--PE	Text-Diagnosis	
2530	R^	R	Text--DX Proc--X-ray/Scan	Text-Diagnosis	
2540	R^	R	Text--DX Proc--Scopes	Text-Diagnosis	
2550	R^	R	Text--DX Proc--Lab Tests	Text-Diagnosis	
2560	R^	R	Text--DX Proc--Op	Text-Diagnosis	
2570	R^	R	Text--DX Proc--Path	Text-Diagnosis	
2580	R^	R	Text--Primary Site Title	Text-Diagnosis	
2590	R^	R	Text--Histology Title	Text-Diagnosis	
2600	R^	R	Text--Staging	Text-Diagnosis	
2610	R^	R	RX Text--Surgery	Text-Treatment	
2620	R^	R	RX Text--Radiation (Beam)	Text-Treatment	
2630	R^	R	RX Text--Radiation Other	Text-Treatment	
2640	R^	R	RX Text--Chemo	Text-Treatment	
2650	R^	R	RX Text--Hormone	Text-Treatment	
2660	R^	R	RX Text--BRM	Text-Treatment	
2670	R^	R	RX Text--Other	Text-Treatment	
2800	RH*	RH*	CS Tumor Size	Stage/Prognostic Factors	
2810	RH*	RH*	CS Extension	Stage/Prognostic Factors	
2820	RH*	RH*	CS Tumor Size/Ext Eval	Stage/Prognostic Factors	
2830	RH*	RH*	CS Lymph Nodes	Stage/Prognostic Factors	
2840	RH*	RH*	CS Lymph Nodes Eval	Stage/Prognostic Factors	
2850	RH*	RH*	CS Mets at DX	Stage/Prognostic Factors	

2860	RH*	RH*	CS Mets Eval	Stage/Prognostic Factors	
2861	RH*	RH*	CS Site-Specific Factor 7	Stage/Prognostic Factors	
2862	RH*	RH*	CS Site-Specific Factor 8	Stage/Prognostic Factors	
2863	RH*	RH*	CS Site-Specific Factor 9	Stage/Prognostic Factors	
2864	RH*	RH*	CS Site-Specific Factor10	Stage/Prognostic Factors	
2865	RH*	RH*	CS Site-Specific Factor11	Stage/Prognostic Factors	
2866	RH*	RH*	CS Site-Specific Factor12	Stage/Prognostic Factors	
2867	RH*	RH*	CS Site-Specific Factor13	Stage/Prognostic Factors	
2868	RH*	RH*	CS Site-Specific Factor14	Stage/Prognostic Factors	
2869	RH*	RH*	CS Site-Specific Factor15	Stage/Prognostic Factors	
2870	RH*	RH*	CS Site-Specific Factor16	Stage/Prognostic Factors	
2871	RH*	RH*	CS Site-Specific Factor17	Stage/Prognostic Factors	
2879	RH*	RH*	CS Site-Specific Factor25	Stage/Prognostic Factors	
2880	RH*	RH*	CS Site-Specific Factor 1	Stage/Prognostic Factors	
2890	RH*	RH*	CS Site-Specific Factor 2	Stage/Prognostic Factors	
2900	RH*	RH*	CS Site-Specific Factor 3	Stage/Prognostic Factors	
2910	RH*	RH*	CS Site-Specific Factor 4	Stage/Prognostic Factors	
2920	RH*	RH*	CS Site-Specific Factor 5	Stage/Prognostic Factors	
2930	RH*	RH*	CS Site-Specific Factor 6	Stage/Prognostic Factors	
2935	RH*	RH*	CS Version Input Original	Stage/Prognostic Factors	
2936	RH*	RH*	CS Version Derived	Stage/Prognostic Factors	
2937	RH*	RH*	CS Version Input Current	Stage/Prognostic Factors	
3020	RH*	RH*	Derived SS2000	Stage/Prognostic Factors	
3050	RH*	RH*	Derived SS2000--Flag	Stage/Prognostic Factors	
3170	R	R	RX Date Mst Defn Srg	Treatment-1st Course	
3171	R	R	RX Date Mst Defn Srg Flag	Treatment-1st Course	
3250	R	R	RX Summ--Transplnt/Endocr	Treatment-1st Course	
3400	RH*	RH*	Derived AJCC-7 T	Stage/Prognostic Factors	
3402	RH*	RH*	Derived AJCC-7 T Descript	Stage/Prognostic Factors	
3410	RH*	RH*	Derived AJCC-7 N	Stage/Prognostic Factors	
3412	RH*	RH*	Derived AJCC-7 N Descript	Stage/Prognostic Factors	
3420	RH*	RH*	Derived AJCC-7 M	Stage/Prognostic Factors	
3422	RH*	RH*	Derived AJCC-7 M Descript	Stage/Prognostic Factors	
3430	RH*	RH*	Derived AJCC-7 Stage Grp	Stage/Prognostic Factors	

3769	RH	RH	Over-ride CS 20	Edit Overrides/Conversion History/System Admin	2012-2015
3800	D	D	Schema ID	Stage/Prognostic Factors	New
3804	RN	CoC facilities only	Adenopathy	Stage/Prognostic Factors	New
3806	RN	CoC facilities only	AFP Post-Orchiectomy Range	Stage/Prognostic Factors	New
3808	RN	CoC facilities only	AFP Pre-Orchiectomy Range	Stage/Prognostic Factors	New
3809	RN	CoC facilities only	AFP Pretreatment Interpretation	Stage/Prognostic Factors	New
3811	RN	CoC facilities only	Anemia	Stage/Prognostic Factors	New
3812	RN	CoC facilities only	B symptoms	Stage/Prognostic Factors	New
3816	R	R	Brain Molecular Markers	Stage/Prognostic Factors	New
3817	RN	CoC facilities only	Breslow Tumor Thickness	Stage/Prognostic Factors	New
3826	RN	CoC facilities only	Estrogen Receptor Percent Positive or Range	Stage/Prognostic Factors	New
3827	R	R	Estrogen Receptor Summary	Stage/Prognostic Factors	New
3828	RN*	CoC facilities only	Estrogen Receptor Total Allred Score	Stage/Prognostic Factors	New
3829	RN	CoC facilities only	Esophagus and EGJ Tumor Epicenter	Stage/Prognostic Factors	New
3835	R	R	Fibrosis Score	Stage/Prognostic Factors	New
3837	RN	CoC facilities only	Gestational Trophoblastic Prognostic Scoring Index	Stage/Prognostic Factors	New
3838	RN	CoC facilities only	Gleason Patterns Clinical	Stage/Prognostic Factors	New
3839	RN	CoC facilities only	Gleason Patterns Pathological	Stage/Prognostic Factors	New
3840	RN	R	Gleason Score Clinical	Stage/Prognostic Factors	New
3841	RN	R	Gleason Score Pathological	Stage/Prognostic Factors	New
3842	RN	CoC facilities only	Gleason Tertiary Pattern	Stage/Prognostic Factors	New
3843	R	R	Grade Clinical	Stage/Prognostic Factors	New
3844	RN	R*	Grade Pathological	Stage/Prognostic Factors	New - record either 3844 or 3845 as applicable
3845	RN	R*	Grade Post Therapy	Stage/Prognostic Factors	New - record either 3844 or 3845 as applicable
3847	RN	CoC facilities only	hCG Post-orchiectomy Range	Stage/Prognostic Factors	New
3849	RN	CoC facilities only	hCG Pre-orchiectomy Range	Stage/Prognostic Factors	New
3855	R	R	HER2 Overall Summary	Stage/Prognostic Factors	New
3856	R	R	Heritable Trait	Stage/Prognostic Factors	New
3857	RN	CoC facilities only	High Risk Cytogenetics	Stage/Prognostic Factors	New
3865	RN	CoC facilities only	KIT Gene Immunohistochemistry	Stage/Prognostic Factors	New
3867	R	R	LDH Post-Orchiectomy Range	Stage/Prognostic Factors	New

3868	R	R	LDH Pre-Orchiectomy Range	Stage/Prognostic Factors	New
3869	R	R	LDH Pretreatment Level	Stage/Prognostic Factors	New
3870	R	R	LDH Upper Limits of Normal	Stage/Prognostic Factors	New
3882	RN	CoC facilities only	LN Positive Axillary Level I-II	Stage/Prognostic Factors	New
3883	RN	CoC facilities only	LN Size	Stage/Prognostic Factors	New
3885	RN	CoC facilities only	Lymphocytosis	Stage/Prognostic Factors	New
3887	RN	CoC facilities only	Measured Basal Diameter	Stage/Prognostic Factors	New
3888	RN	CoC facilities only	Measured Thickness	Stage/Prognostic Factors	New
3890	RS*	RS*	Microsatellite Instability (MSI)	Stage/Prognostic Factors	New
3895	RN	CoC facilities only	Multigene Signature Results	Stage/Prognostic Factors	New
3904	RN	CoC facilities only	Oncotype Dx Recurrence Score-Invasive	Stage/Prognostic Factors	New
3906	RN	CoC facilities only	Oncotype Dx Risk Level-Invasive	Stage/Prognostic Factors	New
3907	RN	CoC facilities only	Organomegaly	Stage/Prognostic Factors	New
3910	RN	CoC facilities only	Peripheral Blood Involvement	Stage/Prognostic Factors	New
3911	RN	CoC facilities only	Peritoneal Cytology	Stage/Prognostic Factors	New
3914	RN	CoC facilities only	Progesterone Receptor Percent Positive or Range	Stage/Prognostic Factors	New
3915	R	R	Progesterone Receptor Summary	Stage/Prognostic Factors	New
3916	RN*	CoC facilities only	Progesterone Receptor Total Allred Score	Stage/Prognostic Factors	New
3917	RN	CoC facilities only	Primary Sclerosing Cholangitis	Stage/Prognostic Factors	New
3920	RN	R	PSA (Prostatic Specific Antigen) Lab Value	Stage/Prognostic Factors	New
3923	RN	CoC facilities only	S Category Clinical	Stage/Prognostic Factors	New
3924	RN	CoC facilities only	S Category Pathological	Stage/Prognostic Factors	New
3926	RN	CoC facilities only	Schema Discriminator 1	Stage/Prognostic Factors	New
3927	RN	CoC facilities only	Schema Discriminator 2	Stage/Prognostic Factors	New
3928	RN	CoC facilities only	Schema Discriminator 3	Stage/Prognostic Factors	New
3930	RN	CoC facilities only	Serum Albumin Pretreatment Level	Stage/Prognostic Factors	New
3931	RN	CoC facilities only	Serum Beta-2 Microglobulin Pretreatment Level	Stage/Prognostic Factors	New
3932	R	R	LDH Pretreatment Lab Value	Stage/Prognostic Factors	New
3933	RN	CoC facilities only	Thrombocytopenia	Stage/Prognostic Factors	New

			R = Required; R* = Required, when available; RS = Required, site-specific; RS* required, site-specific, when available; D* = derived, site-specific; RN = implement according to NPCR stage transition plan; RH= required historically; RH* = Required historically, when available; CoC = collected only by CoC facilities and any others who choose to collect these items; CR = central registry database item		
--	--	--	---	--	--